Abstract: Provided is a sulfonamide derivate represented by the general formula (I), a preparation method thereof, a pharmaceutical composition containing said derivative, and the use thereof as a therapeutic agent, especially as a Lysine Acetyl Transferase (KAT) inhibitor and the use of same in the preparation of a medicament for the treatment and/or prevention of cancer.

Abstract: Provided are a fused bicyclic derivative, a pharmaceutically acceptable salt, a crystal form thereof and a preparation method therefor. Specifically, provided are a hydrochloride, a mesylate, an acetate and a tartrate of the compound of formula (I), and a preparation method therefor and a crystal form thereof.

Abstract: A chimeric compound for targeted degradation of androgen receptor protein, a preparation method therefor, and a medical use thereof. Specifically, the present invention relates to a spiro compound represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the spiro compound, and uses thereof as a therapeutic agent, in particular a use as an androgen receptor degradation agent and a use in the preparation of a drug for treating and/or preventing androgen receptor mediated or dependent diseases or conditions.

Abstract: The present disclosure relates to a nitrogen-containing tetracyclic compound, a preparation method therefor, and a medical use thereof. In particular, the present disclosure relates to the nitrogen-containing tetracyclic compound represented by general formula (IM), a preparation method therefor, a pharmaceutical composition containing said compound, the use thereof as a therapeutic agent, especially as a KRAS G12C inhibitor, and the use thereof in the preparation of medicaments for the treatment and/or prevention of tumors.

Abstract: The present disclosure relates to a crystal form of a pyridopyrimidine derivative and a preparation method thereof, and specifically relates to the crystal form of the compound of formula (I) and a preparation method thereof. The new crystal form has good physical and chemical properties, thereby facilitating clinical treatments.

Abstract: The present disclosure relates to a tetrahydronaphthalene compound, and a preparation method therefor and the use thereof in medicine. Specifically, the present disclosure relates to a tetrahydronaphthalene compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof as a therapeutic agent, in particular the use thereof as an estrogen receptor degrader, the use in the preparation of a drug for treating and/or preventing estrogen receptor-mediated or dependent diseases or conditions and the use in the preparation of a drug for treating and/or preventing diseases or conditions by means of degrading a target protein.

Abstract: Provided in the present disclosure is an antibody or fragment thereof against a human growth and differentiation factor 15 (GDF15). Further provided in the present disclosure is the use of the antibody or fragment thereof in the preparation of a drug for treating diseases or conditions. The antibody or fragment thereof provided in the present disclosure can bind to human GDF15 with high affinity and specificity, blocks the interaction of GDF15 with receptor GFRAL thereof, and has a longer half-life period in vivo in comparison with antibodies of the same kind.

Abstract: A single molecule detection method based on grating scanning recognition, in which a large number of capture beads are scattered on a bead retaining plate (or a detection chip). At least part of the capture beads are specifically bound with an analyte, and each analyte is bound with a luminescent substance. Grating ports of a grating detection device are used to scan the capture beads column by column from the capture beads arranged at one end. The number of the capture beads bound with a marker is synchronously counted. The capture beads on the whole bead retaining plate are scanned through transverse relative movement between the grating ports and the capture beads. The total number of analytes can be obtained after scanning is completed.

Abstract: A method for mixing immunoassay reagent in immunoassay analysis device and an immunoassay analysis device are provided. The method disperses aggregated magnetic beads in a reagent tray of the immunoassay analysis device by keeping an immunoassay reagent tube containing the immunoassay reagent in a variable speed state during rotation and/or by exerting an impact force on the immunoassay reagent tube during rotation of the immunoassay reagent tube, so as to keep the immunoassay reagent in a mixed state. The method can mix the immunoassay reagent, avoid the phenomenon of magnetic beads' aggregation and ensure the accuracy of the testing results.

Abstract: Disclosed are fused imidazole derivatives, preparation methods therefor and medical uses thereof. Specifically, the present disclosure relates to a fused imidazole derivative as shown in general formula (IM), a preparation method therefor, a pharmaceutical composition containing the derivative, and the use of same as a therapeutic agent, in particular the use thereof as a GLP-1 receptor agonist, and the use thereof in the preparation of drugs for the treatment and/or prevention of diabetes.

Abstract: Provided are a pharmaceutically acceptable salt and a crystalline form of a GLP-1 receptor agonist and a preparation method therefor. Specifically, provided are a pharmaceutically acceptable salt and a crystalline form of a compound 2-((4-((S)-3-(4-chloro-2-fluorophenyl)-2,3-dihydrobenzo[b][1,4]dioxane-5-yl)piperidin-1-yl)methyl)-1-(((S)-oxe-tane-2-yl)methyl)-1H-benzo[d]imidazole-6-formic acid.

Abstract: This disclosure relates to glasses and glass articles. The glass articles include flat glass suitable for use in display devices, such as electronic devices, including smartphones, smart watches and tablet computers. A method of making glass articles is described as well.

Abstract: Disclosed are fused imidazole derivatives, preparation methods therefor and medical uses thereof. Specifically, the present disclosure relates to a fused imidazole derivative as shown in general formula (IM), a preparation method therefor, a pharmaceutical composition containing the derivative, and the use of same as a therapeutic agent, in particular the use thereof as a GLP-1 receptor agonist, and the use thereof in the preparation of drugs for the treatment and/or prevention of diabetes.

Abstract: A method and an apparatus for satellite laser broadband demodulation are provided. The method includes: setting a residual carrier to a carrier acquisition range of a receiver, pulling the residual carrier to an MHz level by adjusting a frequency of a local oscillator laser, and obtaining a precise carrier frequency according to an accurate frequency acquisition, such that the residual carrier enters a fast acquisition band of a carrier tracking phase-locked loop. After carrier acquisition is achieved, carrier tracking and data recovery processing are performed. According to the present disclosure, signal equalization of an ultra-high bandwidth/ultra-high bit rate can be implemented, and carrier acquisition, tracking, and demodulation are quickly achieved for a modulation signal in a high dynamic range.

Abstract: The present invention relates to benzimidazole derivatives of formula (I) as inhibitors of retinoid-related orphan receptor gamma (ROR?) protein, pharmaceutical compositions containing the compounds, preparation methods thereof, and the use of the compounds as therapeutic agents for the treatment of ROR?-mediated diseases or disorders.

Abstract: A chemically toughened glass article is provided that has a thickness (t) of equal to or less than 0.4 mm, a first surface, a second surface, and a compressive stress region that is defined by a compressive stress (CS) of at least 100 MPa and at least one edge connecting the first surface and the second surface. The at least one edge has at least one chamfer with a chamfer width (A) and a chamfer height (B). The chamfer has a ratio of chamfer width/chamfer height (A/B) of between 1.5-20 and the chamfer has a ratio of chamfer width/glass thickness (A/t) of at least 0.5.

Abstract: The present disclosure relates to a pyrrolo benzodiazepine derivative and a conjugate, preparation method and use thereof. In particular, the present disclosure relates to a compound of formula (DL) and a antibody-drug conjugate thereof, a pharmaceutical composition containing same, and a use thereof in the preparation of a medicament for the treatment of cancer. The definitions of groups in the general formula (DL) are as defined in the description.

Abstract: Disclosed are a pyridopyrimidine derivative as shown in general formula (I), a preparation method therefor and a pharmaceutical composition containing the derivative, and the use thereof as a therapeutic agent, particularly as a TLR8 agonist, wherein each substituent of general formula (I) is the same as those defined in the description.

Abstract: A cross-device authentication method includes: a login authentication initiation device that determines, from at least one electronic device, a login authentication device of a to-be-authenticated application, where an authentication application is installed on the login authentication device, and the authentication application is logged in; and sends a first login authentication request to the login authentication device; the login authentication device displays an account login interface of the authentication application based on the first login authentication request, where the account login interface includes a first button indicating to approve authorization and a second button indicating to reject authorization; obtains an operation instruction when a user performs a tapping operation on a first button or a second button; and feeds back a first login authentication response to the login authentication initiation device.

Abstract: The present invention relates to a fused tricyclic compound, a preparation method therefor, and an application thereof in medicine. Specifically, the present invention relates to a fused tricyclic compound represented by general formula (1), a preparation method therefor, a pharmaceutical composition containing the compound, and a use thereof as a therapeutic agent, particularly a use as a TLR7/8/9 inhibitor and a use in preparing a drug for the treatment and/or prevention of inflammatory and autoimmune diseases. The definition of each group in general formula (1) is as defined in the description.